Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals
, , , , , , , and .
Infection and Immunity 72 (1): 332--337 (January 2004)PMID: 14688112.

Asplenic individuals are known to be at increased risk of infection with encapsulated bacteria. Recent United Kingdom recommendations stated that this at-risk group should receive one dose of the meningococcal serogroup C conjugate (MCC) vaccine. However, the immune response of asplenic individuals to MCC vaccine is unknown. The immune response of asplenics (n = 130) to immunization with the MCC vaccine was investigated. Asplenic individuals had a significantly lower geometric mean titer (GMT) (157.8; 95\% confidence interval CI, 94.5 to 263.3) of bactericidal antibody in serum (SBA) than an age-matched control group (n = 48) (1448.2; 95\% CI, 751.1 to 2792.0). However, 80\% of asplenic individuals achieved the proposed protective SBA titer of \textgreater or =8. No differences were observed between the two groups in the serogroup C-specific immunoglobulin G geometric mean concentration. A significant reduction in SBA GMT or the number of responders achieving an SBA titer of \textgreater or =8 was observed if the reason for splenectomy was a medical cause or if MCC vaccination occurred \textless10 years after splenectomy. Individuals (n = 29) who did not achieve an SBA titer of \textgreater or =16 were offered a second dose of MCC vaccine. Analysis of the SBA response revealed that 61\% (14 of 23) of the individuals who received a second dose achieved a protective titer. In total, 93\% of asplenic individuals achieved a titer of \textgreater or =8 following MCC vaccination (one or two doses combined). We recommend that, following vaccination of asplenics, either the level of functional antibody should be determined, with a second dose of MCC vaccine offered to nonresponders, or two doses of MCC vaccine should be routinely offered.
This publication has not been reviewed yet.

rating distribution
average user rating0.0 out of 5.0 based on 0 reviews
    Please log in to take part in the discussion (add own reviews or comments).